Last update June 23, 2022
Likely Compatibility
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
فلوفينازين is Fluphenazine in Arabic.
Is written in other languages:فلوفينازين is also known as
فلوفينازين belongs to these groups or families:
Main tradenames from several countries containing فلوفينازين in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 2.7 | % |
Molecular weight | 438 | daltons |
Protein Binding | 99 | % |
VD | 3 | l/Kg |
pKa | 15.59 | - |
Tmax | 2; depot: 8-10 | hours |
T½ | 4.4 - 16.4; depot: 336 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Typical, first-generation antipsychotic. Prochlorperazine is a phenothiazine derivative with general properties similar to those of chlorpromazine. It is used in the treatment of schizophrenia, bipolar disorder, and severe anxiety. Oral, intramuscular or subcutaneous administration three or four times a day.
Since the last update we have not found published data on its excretion in breastmilk.
Its pharmacokinetic data (very wide volume of distribution and high percentage of protein binding) make it highly unlikely that significant quantities will pass into breast milk.
Its very low oral bioavailability makes it difficult for it to pass to the infant plasma from ingested breast milk, except in premature infants and in the immediate neonatal period in which there may be greater intestinal permeability.
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable (Parikh 2014, Klinger 2013, WHO 2002), especially during the neonatal period and in the event of prematurity.
During breastfeeding, depot forms should be avoided because their long half-life can facilitate greater excretion in breast milk.
See below the information of this related product: